Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.66 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.60 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.50 |
| ▸ | MAOB | P27338 | 6/20 | 0.48 |
| ▸ | MAOA | P21397 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | CA3 | P07451 | 1/20 | 0.48 |
| ▸ | CA4 | P22748 | 1/20 | 0.48 |
| ▸ | CA6 | P23280 | 1/20 | 0.48 |
| ▸ | CA7 | P43166 | 1/20 | 0.48 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.48 |
| ▸ | NOS1 | P29475 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1550777 | 0.89 | ALOX5 (0.63) | CYP3A4ALOX5NPC1RAB9APRMT5 | |
| SCHEMBL9015202 | 0.81 | CYP3A4 (0.66) | CYP3A4ALOX5NPC1RAB9AMAOB | |
| SCHEMBL23273961 | 0.81 | CYP3A4 (0.54) | CYP3A4ALOX5NPC1RAB9APRMT5 | |
| SCHEMBL29971250 | 0.81 | CYP3A4 (0.54) | CYP3A4ALOX5NPC1RAB9APRMT5 | |
| SCHEMBL841728 | 0.79 | CYP3A4 (1.00) | CYP3A4ALOX5NPC1RAB9APRMT5 | |
| SCHEMBL30125417 | 0.79 | CYP3A4 (1.00) | CYP3A4ALOX5NPC1RAB9APRMT5 | |
| SCHEMBL19101889 | 0.79 | CYP3A4 (0.43) | CYP3A4ALOX5PRMT5CA1CA2 | |
| SCHEMBL1042727 | 0.79 | MEN1 (0.50) | CYP3A4MEN1KMT2ALMNAGAA | |
| SCHEMBL31580904 | 0.79 | CYP3A4 (0.62) | CYP3A4ALOX5NPC1RAB9ALMNA | |
| SCHEMBL24637914 | 0.79 | SMN1; SMN2 (0.51) | CYP3A4ALOX5NPC1RAB9APRMT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105037266-A | Antibacterial chloroxoquinoline derivative | WANG ZIHOU | 2015-11-11 | — | — | CN | claimed |
| CN-105017145-A | Chloroxoquinoline derivative with anti-tumor activity | WANG ZIHOU | 2015-11-04 | — | — | CN | claimed |
| CN-105017145-B | 7-chloro-4-oxo-quinoline derivative with antitumor activity | 王子厚 | 2017-12-05 | — | — | CN | disclosed |
| CN-105037266-B | 7-chloro-4-oxo-quinoline derivative for antibacterial | 王子厚 | 2017-07-28 | — | — | CN | disclosed |
| CN-105037266-A | Antibacterial chloroxoquinoline derivative | WANG ZIHOU | 2015-11-11 | — | — | CN | disclosed |
| CN-105017145-A | Chloroxoquinoline derivative with anti-tumor activity | WANG ZIHOU | 2015-11-04 | — | — | CN | disclosed |
| CN-103864681-B | Chloroxoquinoline derivatives for antibacterial use | WANG ZIHOU (CN) | 2015-09-02 | — | — | CN | disclosed |
| CN-103864680-B | Chloroxoquinoline derivative with antineoplastic activity | WANG ZIHOU (CN) | 2015-09-02 | — | — | CN | disclosed |
| EP-2270006-A1 | Pyridazine derivatives useful as vanilloid receptor ligands | Amgen, Inc (US) | 2011-01-05 | — | — | EP | disclosed |
| US-7332511-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2008-02-19 | — | — | US | disclosed |
| US-7332511-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2008-02-19 | — | — | US | disclosed |
| US-7148221-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2006-12-12 | — | — | US | disclosed |
| US-7144888-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2006-12-05 | — | — | US | disclosed |
| EP-1717220-A2 | Vanilloid receptor ligands and their use in treatments | Amgen, Inc (US) | 2006-11-02 | — | — | EP | disclosed |
| EP-1688408-A2 | Vanilloid receptor ligands and their use in treatments | Amgen, Inc (US) | 2006-08-09 | — | — | EP | disclosed |
| US-20050277631-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. | 2005-12-15 | — | — | US | disclosed |
| US-20050272777-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. | 2005-12-08 | — | — | US | disclosed |
| EP-1546116-A1 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | Amgen Inc. (US) | 2005-06-29 | — | — | EP | disclosed |
| US-20040082780-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN, INC. | 2004-04-29 | — | — | US | disclosed |
| WO-2004014871-A1 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | AMGEN INC. (US) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050272777-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV2, TRPV3 | CYP3A4 1962/4885ALOX5 839/4885NPC1 2938/4885 |
| US-20050277631-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV2, TRPV3 | CYP3A4 1962/4885ALOX5 839/4885NPC1 2938/4885 |
| US-20040082780-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV2, TRPV3 | CYP3A4 2078/4885ALOX5 854/4885NPC1 2453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.